Literature DB >> 8560482

Pharmacokinetics and interspecies scaling of recombinant human factor VIII.

J Mordenti1, G Osaka, K Garcia, K Thomsen, V Licko, G Meng.   

Abstract

Recombinant human (rh) factor VIII is a glycoprotein consisting of multiple polypeptides with relative mobilities (M(r)) ranging from 80,000 to 210,000. It is produced in mammalian cells. Single-dose intravenous pharmacokinetic studies were conducted with rh factor VIII (Kogenate rh Antihemophilic Factor, Miles, Inc.) in male mice (21.0-25.8 g) and rats (252.0-254.2 g). Each species received 400 IU/kg, and blood was collected up to 12 hr (mice) or 32.5 hr (rats) post-dose. Immunoreactive factor VIII concentrations in plasma were quantified by a sensitive and specific ELISA. In both species, the disposition profiles were described by the sum of two exponentials. The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr. In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr. These pharmacokinetic parameters for rh factor VIII in animals and human rh factor VIII pharmacokinetic parameters from the literature were evaluated to determine if the parameters can be represented by the allometric relationship, Y = aWb, where Y is the pharmacokinetic parameter, and W is body weight. The following allometric relations were obtained for rh factor VIII: clearance (ml/hr) = 10.4W0.69, half-life (hr) = 7.5 W0.18, initial volume of distribution (ml) = 43.6 W1.04, and steady-state volume of distribution (ml) = 99.1 W0.84. The allometric exponents for each parameter conformed to theory and were within the range of values commonly observed for xenobiotics and therapeutic proteins. These studies suggest that the pharmacokinetics of rh factor VIII in laboratory animals are predictive of the disposition in humans despite the complex nature of its biological interactions and the chemical diversity of the purified material.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560482     DOI: 10.1006/taap.1996.0008

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  12 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

3.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

4.  Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2014-01-02       Impact factor: 1.627

5.  Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.

Authors:  Qin Wang; Douglas Shorten; Xin Xu; Gray D Shaw; Robert G Schaub; Christopher Shea; Jonathan Brooks; Dianne Sako; Erin Wiswall; Jin Xu; Pamela Szklut; Vikram S Patel
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

6.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

7.  Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.

Authors:  Antonia Follenzi; Daniel Benten; Phyllis Novikoff; Louisa Faulkner; Sanj Raut; Sanjeev Gupta
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

8.  A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis.

Authors:  Brian Spencer; Inder Verma; Paula Desplats; Dinorah Morvinski; Ed Rockenstein; Anthony Adame; Eliezer Masliah
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

9.  Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66.

Authors:  W L Chiou; G Robbie; S M Chung; T C Wu; C Ma
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

10.  Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.

Authors:  Michael Neyman; Jamie Gewirtz; Mortimer Poncz
Journal:  Blood       Date:  2008-06-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.